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Abstract
Previous studies have demonstrated the effective control of cytomegalovirus (CMV) infections post haematopoietic stem
cell transplant through the adoptive transfer of donor derived CMV-specific T cells (CMV-T). Strategies for manufacturing
CMV immunotherapies has involved a second leukapheresis or blood draw from the donor, which in the unrelated donor
setting is not always possible. We have investigated the feasibility of using an aliquot of the original G-CSF-mobilized graft
as a starting material for manufacture of CMV-T and examined the activation marker CD25 as a targeted approach for
identification and isolation following CMVpp65 peptide stimulation. CD25+ cells isolated from G-CSF-mobilized apheresis
revealed a significant increase in the proportion of FoxP3 expression when compared with conventional non-mobilized
CD25+ cells and showed a superior suppressive capacity in a T cell proliferation assay, demonstrating the emergence of a
population of Tregs not present in non-mobilized apheresis collections. The expansion of CD25+ CMV-T in short-term
culture resulted in a mixed population of CD4+ and CD8+ T cells with CMV-specificity that secreted cytotoxic effector
molecules and lysed CMVpp65 peptide-loaded phytohaemagglutinin-stimulated blasts. Furthermore CD25 expanded cells
retained their suppressive capacity but did not maintain FoxP3 expression or secrete IL-10. In summary our data indicates
that CD25 enrichment post CMV stimulation in G-CSF-mobilized PBMCs results in the simultaneous generation of both a
functional population of anti-viral T cells and Tregs thus illustrating a potential single therapeutic strategy for the treatment
of both GvHD and CMV reactivation following allogeneic haematopoietic stem cell transplantation. The use of G-CSF-
mobilized cells as a starting material for cell therapy manufacture represents a feasible approach to alleviating the many
problems incurred with successive donations and procurement of cells from unrelated donors. This approach may therefore
simplify the clinical application of adoptive immunotherapy and broaden the approach for manufacturing multi-functional T
cells.
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Introduction
Cytomegalovirus (CMV) reactivation continues to be a signif-
icant cause of morbidity and mortality following allogeneic
haematopoietic stem cell transplantation (aHSCT) [1,2] with the
incidence of CMV disease being reported to be as high as 70% [3].
Several strategies have been employed in the manufacture of
donor-derived CMV-specific T cells (CMV-T) for adoptive
transfer over the last two decades that have successfully
demonstrated both safety and efficacy in restoring antiviral
immunity [4–10]. More recently the direct selection of c-secreting
(IFN-c) cells in response to CMVpp65 peptide stimulation [11,12]
has simplified generation of CMV-T, significantly reduced the
manufacturing time and has also been successfully used to select T
cells specific for adenovirus (AdV) and Epstein Barr virus (EBV)
for clinical use [13,14]. Isolation of antigen-specific T cells through
the identification of activation markers that are up-regulated after
T cell activation is also a promising alternative. T cell activation
markers offer an increased sensitivity over approaches such as
IFN-c secretion as they are independent of cytokine secretion and
therefore could allow the isolation of increased numbers of
antigen-specific T cells. Several T cell activation markers have
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been identified including CD25, CD69, CD137 and CD154 [15–
20] with differing temporal dynamics that allow for simultaneous
detection and enrichment. The availability of good manufacturing
practice (GMP) compliant CD25 antibodies for clinical use makes
the selection of CMV-T through CD25 selection a feasible option.
Indeed several groups have investigated CD25 in large scale
clinical manufacture for potential use in adoptive transfer [21,22]
due to the commercial availability of CD25 reagents.
To date models for CMV-T manufacture have focussed
primarily on using peripheral blood mononuclear cells (PBMCs)
collected by leukapheresis from the original HSCT donor. The
procurement of an additional apheresis for CMV-T manufacture
is associated with some degree of difficulty especially in the
unrelated donor setting where donor refusal, registry refusal and
scheduling difficulties can prevent collection. The prospect of
manufacturing antigen-specific T cells from an aliquot of the
original HSCT obtained by leukapheresis after mobilization by
recombinant human granulocyte-colony stimulating factor (G-
CSF) as an alternative PBMCs source is attractive. Murine and
human studies have suggested that G-CSF-mobilization inhibits
type 1 cytokine production by T cells, through inhibition of
secretion at a single cell level as well as reducing the fraction of
cytokine-secreting cells in the periphery, arguing against the use of
these cells for adoptive immunotherapy [23–27]. Furthermore
extensive gene expression profiling in G-CSF-mobilized PBMCs
has revealed the up-regulation of genes related to T helper cells
type 2 (TH2) and Treg cells and down-regulation of genes
associated with T helper cells type 1 (TH1), cytotoxicity, antigen
presentation and GvHD [28]. However there has been little
published data with regard to the effect of G-CSF on the anti-viral
T cell response and the influence of G-CSF in this regard, beyond
the time of apheresis. The clinical use of G-CSF-mobilized donor
lymphocytes administered for therapy of relapse post aHSCT in
acute myeloid leukaemia (AML) has demonstrated efficacy with a
similar graft versus leukaemia (GvL) response when compared
with conventional non-mobilized donor lymphocytes [29,30].
These results alleviate some of the major concerns surrounding the
feasibility of using G-CSF-mobilized lymphocytes as a starting
material for the manufacture of anti-viral immunotherapies. We
have published our previous findings that demonstrated the
feasibility of employing the use of G-CSF-mobilized PBMCs as an
effective strategy for manufacture of CMV-T with the retention of
Figure 1. Identification and Isolation of CD25+ CMVpp65-specific T cells in G-CSF-mobilized and non-mobilized PBMCs. G-CSF-
mobilized (n=6) and non-mobilized PBMCs (n= 5) were stimulated for 24 hours or left untouched (negative control) and samples taken at 1, 4, 6, 16
and 24 hours for analysis of CD25 expression amongst CD3+ T cells (A). Purity and yield of CD25 expressing cells was determined from within the
CD3+ population following selection (B). Evaluation of FoxP3 expression in CD4+ CD25+ T cells in G-CSF-mobilized and non-mobilized PBMCs was
assessed in pre-stimulated, CMVpp65 stimulated and post CD25+ selection after gating on CD3+ CD4+ T cells (C). Cumulative data of FoxP3
expression was assessed by analysing CD25+FoxP3+ and CD25+FoxP32 populations per 10,000 CD4+ T cells in both G-CSF-mobilized and non-
mobilized PBMCs (D). **p,0.01 and *p,0.05 in an unpaired t test comparing the absolute number of CD25+FoxP3+ cells. Stim, stimulated; Mob,
mobilized; N-Mob, non-mobilized; Neg, negative.
doi:10.1371/journal.pone.0085911.g001
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functional CMV-specific cytotoxicity comparable with non-mobi-
lized PBMCs, using CD154 based selection [31]. But the
translation of this particular approach is currently restricted by
the non-availability of a GMP-compliant anti-CD154 antibody.
More recently the generation and adoptive transfer of CMV-T cell
lines expanded from G-CSF-mobilized PBMCs in short term
culture has been demonstrated in a phase I/II clinical trial, where
seven patients received CMV-T cell products [32]. However, the
widespread application of short-term culture manufacturing
processes can be complex to translate into cellular therapy
laboratories, from a both a regulatory and GMP compliant
perspective.
In this study we explore the feasibility of using CD25-based
enrichment of CMV-T from G-CSF-mobilized PBMCs due to the
relative simplicity and rapidity of current direct selection methods.
Identification of antigen-specific T cells through CD25 expression
can be confounded by the similar CD25 expression pattern
exhibited by regulatory T cells (Tregs). Tregs are a subset of CD4+
T cells that are suppressive in nature and regulate responses
towards tumour, foreign and allo-antigens that constitutively
express CD25 [33,34]. The transcription factor forkhead box P3
(FoxP3) has also been identified to play a role in the development
and function of Tregs and is also used as a phenotypic marker of
Tregs [35]. Ukena and colleagues [36] in their studies report the
application of G-CSF resulted in a significant increase in Treg
yield and that cells retain a cytokine profile and phenotype
associated with Treg characteristics and remained highly suppres-
sive. Previous reports in non-mobilized PBMCs have identified
populations of both antigen-specific T cells and Tregs following
CD25 enrichment and argue that the adoptive transfer of both
these populations in a single immunotherapy product could prove
beneficial to recipients of aHSCT who are at risk of both CMV
reactivation and GvHD [21].
We have therefore investigated the phenotype and function of
CMV-T isolated through CD25 expression from G-CSF-mobi-
lized PBMCs with regard to FoxP3 expression and suppressive
capacity and explored the impact of removal of CD4+ CD25+
Tregs from starting populations to augment selectivity of antigen-
specific T cells for adoptive immunotherapy. CD25+ CMV-T
were expanded in short term culture and subsequently analysed
for both CMV-specificity through cytokine profiling and cytotox-
icity together with suppressive function and FoxP3 expression to
ascertain the retention of Tregs.
Figure 2. Suppression of autologous PBMCs by CMV-stimulated CD25+ cells isolated following CMVpp65 stimulation. Suppressive
capacity was assessed in CD25-positive and CD25-negative fractions after magnetic selection following CMVpp65 stimulation between G-CSF-
mobilized (A) and non-mobilized (B) donors. CFSE-labelled PBMCs were cultured at two ratios in the presence of SEB for 5 days. Cumulative data in G-
CSF-mobilized (n= 5) and non-mobilized (n= 5) donors are shown at a ratio of 1:1 (diagonal bars) and 1:2 (shaded bars) PBMCs to CD25+ selected T
cells after calculating percentage of suppression as indicated in the Material and Methods section. Data are presented as mean values with standard
deviation (C). Unlabelled, PBMCs alone (CFSE) and PBMCs with SEB were cultured as experimental controls. **p,0.01, in an unpaired t test.
doi:10.1371/journal.pone.0085911.g002
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Materials and Methods
Blood Donors and Cell Preparation
Prior to sample collection ethical approval was given by the
National Health Service (NHS) Health Research Authority (North
West London Research Ethics Committee) and permission
obtained from the institutional research and development office
of Royal Free London Foundation Trust. After obtaining signed
written informed consent, fresh blood samples were taken from
both G-CSF-mobilized and non-mobilized CMV-seropositive
healthy donors, after a 3–5 hour collection on the COBE Spectra
apheresis system (Caridian BCT, Lakewood, CA). PBMCs were
isolated from all donor samples after density gradient separation
using Lymphoprep (Axis Shield Diagnostics, Dundee, UK) and
subsequently cultured in RPMI 1640 Medium supplemented with
1% antibiotic (Both Life Technologies, Paisley, UK) and 10% heat
inactivated human AB serum (Biosera, Ringmer, UK) at a
concentration of 16107/ml. PBMCs were stimulated for up to
24 hours in flat bottom 6 well culture plates (NUNC, Roskilde,
Denmark) with 1 mg/peptide/ml of CMVpp65 peptide pool
spanning the entire CMVpp65 protein (CMVpp65 Peptivator.
Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated at
37uC/5% CO2. In some experiments freshly isolated PBMCs were
cryopreserved at 1:1 with human serum albumin (HSA) 4.5% (Bio
Products Laboratory Ltd, Elstree, UK) containing 20% DMSO
(WakChemie, Steinbach, Germany) according to standard proto-
cols, for use in future experiments as well as a source of feeder
cells.
Flow Cytometric Analysis
Flow cytometry experiments consisted of four to six colour
panels where a minimum of 50,000 CD3+ events were acquired
after gating of viable lymphocytes using FSC and SSC signals on a
FACScan flow cytometer (Cytek UK) and data analysed using
FlowJo version 7.6 (TreeStar Inc. Ashland, OR). For control
staining of cytokines and activation markers we used PE-
conjugated mouse antibodies of matching isotype and supplier of
the retrospective antibodies. Cells were stained for 15 minutes in
the dark, washed in 2 ml of HBSS for 5 minutes and resuspended
in 200 ml of FACS Flow (BD Bioscience, Franklin Lakes, NJ)
before acquisition.
Figure 3. Effect of CD25 immunomagnetic depletion on CD25+ CMVpp65 CMV-T and CD25+ FoxP3+ Tregs. CD25 expression was
assessed in paired unmanipulated and CD25-depleted G-CSF-mobilized PBMCs following CMVpp65 peptide stimulation (A). FoxP3 expression was
analysed both pre and post CD25-enrichment amongst CD4+ T cells (B–D) and CD25 purity and yield determined following CD25 enrichment (D).
**p,0.01 and *p,0.05 in a paired t test. Neg, negative.
doi:10.1371/journal.pone.0085911.g003
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Time Course Assay of Activation Marker Kinetics
PBMCs isolated from mobilized and non-mobilized donors
were stimulated in 96 well plates at a concentration of 16107/ml
for 24 hours with either CMVpp65 Peptivator or 1 mg/ml of
Staphylococcal Enterotoxin B (SEB. Sigma-Aldrich, Gillingham,
UK) or left untouched. Samples were taken at 1, 4, 6, 16 and 24
hours and stained with APC-conjugated anti-CD3, FITC-conju-
gated anti-CD4, PerCP-conjugated anti-CD8 and PE-conjugated
anti-CD25 (BD Bioscience).
Separation Using Anti-CD25-Microbeads
CD25-Microbeads (Miltenyi Biotec) were used for both the
isolation and depletion of CD25+ cells dependent upon the
experiment being performed. For the isolation of antigen-specific
T cells following CMVpp65 stimulation, cells were labelled with
CD25-microbeads after 16 hour incubation. Labelling was
performed for 15 minutes using 10 ml of microbeads per 107 cells
in 90 ml of CliniMACS buffer. Following incubation and washing
the cell suspension was enriched using MS columns on a
MiniMACS (all Miltenyi Biotec). For CD25 depletion experiments
cells were labelled using 20 ml of microbeads per 107 cells in 80 ml
of CliniMACS buffer. Depletions were performed using LD
columns and sorted on a VarioMACS separator (both Miltenyi
Biotec). All incubation steps were performed at 4–8uC in the dark.
Both enriched and depleted cells were stained with CD3-APC,
CD4-FITC, CD8-PerCP, CD69-APC Cy7 (All BD Bioscience)
and CD25-PE (Miltenyi Biotec).
Identification of T Regulatory Cells by FoxP3 Staining
16106 PBMCs from pre stimulation, CMVpp65 stimulated and
CD25 positive fractions were stained with CD3-APC, CD25-PE,
CD4-APC Cy7 and CD8-PerCP then fixed and permeabilized
using the FoxP3 staining kit (BD Bioscience) before staining with
either FoxP3-Alexa Fluor 488 monoclonal antibody or matched
IgG isotype control. Samples were acquired on the FACScan flow
cytometer with a minimum of 50,000 CD4+ events recorded.
CFSE Based Proliferation Assay
The carboxyfluorecein diacetate succinimidyl ester (CFSE)
based suppression assay was used to assess the suppressive capacity
of CMV-T isolated through the activation marker CD25 after 16
hour stimulation with CMVpp65 peptides and compared directly
against the CD25 negative fraction. PBMCs were labelled with
1 mM of CFSE (CellTrace CFSE, Life Technologies) and cultured
in round bottom 96 well plates (NUNC) with a total of 26105 cells
per well. Depending on the number of effector cells available
CD25+ CMV-T and CD22 PBMCs were added to the cultures at
a ratio of 1:1 and 1:2 of CFSE labelled PBMCs to effectors. Cell
cultures were stimulated with 1 mg/ml of SEB (Sigma-Aldrich) or
2 mg/ml of purified anti-CD3 antibody (Clone HIT3a, Biolegend,
San Diego, CA). In control experiments CFSE labelled and
unlabeled PBMCs were cultured alone. Cultures were incubated
for 5 days at 37uC/5% CO2 before harvesting and cells stained
with CD3-APC and CD69-APC Cy7 (Both BD Biosciences)
antibodies. Samples were acquired on the FACScan flow
cytometer and a minimum of 10,000 CD3+ CFSE+ events
recorded. The frequency of suppression was analysed by gating on
the CD3+ CFSE+ population and the percentage of undivided
cells (CFSEhigh) determined using the CFSE labelled and
unlabelled PBMCs control samples. Percentage of suppression
was calculated as follows: [100– (%CFSElow of CD3+ in the
presence of effectors/%CFSElow of CD3+ in the absence of
effectors) x 100].
Expansion of Antigen-Specific T Cell Lines
After isolation of CD25+ CMV-T, up to 0.256106 cells were
cultured in the presence of 12.56106 (50:1) c-irradiated (30 Gy)
autologous PBMCs to act as feeder cells in 24 well plates with
RPMI 1640 medium containing 10% human AB serum, 1%
antibiotic and supplemented with 10 ng/ml of IL-7 and IL-15
(CellGenix, Freiburg, Germany). Culture medium was replenished
every 2–3 days and cells split when necessary. Cells were expanded
up to a maximum of 24 days before harvest.
Figure 4. Expansion of CD25+ CMVpp65-specific T cells in short term culture. 0.256106 CD25+ T cells were expanded in culture for up to
24 days in the presence of IL-7, IL-15 and 12.56106 irradiated autologous feeder cells (ratio of 1:50) in G-CSF-mobilized and non-mobilized donors.
CD25+ expanded cells were analysed for the proportion of CD8+ (open bars) and CD4+ (grey bars) T cells amongst CD3+ T cells in both G-CSF-
mobilized and non-mobilized donors (A). Expanded cells were assessed for co-expression of CD25 and CD69 following CMVpp65 re-challenge in both
G-CSF-mobilized (n= 5) and non-mobilized (n= 5) expansions (B). Expanded cells were also challenged with control feeders (without CMVpp65
peptides). G-Mob, G-CSF-Mobilized; Non-mob, Non-Mobilized.
doi:10.1371/journal.pone.0085911.g004
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Re-stimulation of Expanded Antigen-Specific T Cell Lines
Expanded cells were restimulated for a period of 5–6 hours with
either CMVpp65 Peptivator loaded autologous PBMCs or
untouched autologous PBMCs as a control, all labelled with
1 mM CFSE (Sigma-Aldrich) at a ratio of 5:1 at a concentration of
16107/ml in 48 well plates. For analysis of intracellular cytokines,
cells were incubated in the presence of anti-CD28 antibody (BD
Bioscience) and 1 mg/ml of Brefeldin A (Sigma-Aldrich) added
after 2 hours. Cells were fixed and permeabilized using Intrastain
(DakoCytomation, Ely, UK) according to the manufacturer’s
instructions and stained with CD25-APC, CD4-PerCP either PE-
conjugated anti-IL-2, anti-TNF-a, anti-Granzyme B, anti-IL-10 or
anti IFN-c and CD69-APC Cy7 (all BD Biosciences) monoclonal
antibodies. For surface staining cells were stained for 15 minutes
with CD4-FITC, CD25-PE, CD8-PerCP, CD3-APC and CD69-
APC Cy7 (all BD Biosciences) monoclonal antibodies.
Cytotoxicity Assay
Autologous PBMCs were stimulated with 3 mg/ml of PHA
(Sigma) for 24 hours and then 20 U/ml of IL-2 for a further 72
hours (Miltenyi Biotec) at a concentration of 16106/ml in RPMI
1640 with 10% AB serum, in 24 well flat bottom plates (NUNC).
PHA blasts were then used as target cells in the killing assay and
loaded with CMVpp65 Peptivator, or left untouched. Loaded
target cells were labelled with Calcein-AM (Life Technologies) at a
concentration of 10 mM and incubated for 1 hour at 37uC. After
four washes in complete medium cells were adjusted to 76104/ml
and added to effector cells at E: T ratios ranging from 20:1 to
0.5:1, in triplicate, in U bottom 96 well plates (NUNC). Triplicate
wells were also set up to measure spontaneous release (target cells
only), maximal release (target cells plus 2% Triton X-100) and
medium alone. After incubation at 37uC/5% CO2 for 4 hours,
100 ml of supernatant was harvested and transferred into new
Figure 5. Qualitative and quantitative assessment of cytokine secretion by expanded cells after antigenic re-challenge. Expanded
CD25+ cells isolated from both G-CSF-mobilized and non-mobilized donors were stimulated with CMVpp65 peptide loaded autologous PBMCs in the
presence of Brefeldin A and purified anti CD28-antibody. Histograms illustrate CMVpp65 rechallenge experiments in representative CD25+
expansions from a G-CSF-mobilized and non-mobilized donor, analysed for IL-2, TNF-a, IFN-c, Granzyme B and IL-10. Open peaks represent isotype
matched controls (A). The combined assessment in G-CSF-mobilized (n= 5) and non-mobilized (n= 5) donors are summarized (B). **p,0.01, in an
unpaired t test. Gra, granzyme; Mob, mobilized.
doi:10.1371/journal.pone.0085911.g005
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plates. Samples were measured using a BMG FLUOstar Galaxy
microplate fluorescence spectrophotometer (MTX Lab Systems
Inc. Vienna, VA) (excitation filter: 48569 nm: band-pass filter:
53069 nm). Data were expressed as arbitrary fluorescent units
(AFU) and percent lysis was calculated using the formula [(test
release-spontaneous release/maximal release-spontaneous release)
x 100].
Figure 6. Cytotoxicity of CD25+ expanded CMV-T. Specific lysis of autologous PHA blasts loaded with CMVpp65 peptides at E:T ratios from
20:1 to 0.5:1 was determined using fluorescent dye Calcein-AM cytotoxicity assay in CD25+ expanded cells. Graphs show pooled data from all
cytotoxicity experiments in G-CSF-mobilized (A; n=4) and non-mobilized (B; n=4) CD25+ expanded CMV-T.
doi:10.1371/journal.pone.0085911.g006
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Statistical Analysis
Analyses were conducted using GraphPad Prism 4.0 (Graph
Pad Software Inc. La Jolla, CA). An unpaired t test was used to
determine the statistical significance between G-CSF-mobilized
and non-mobilized PBMCs which followed a normal distribution.
A paired t test was used for analysing the effect of CD25-
depeletion on CD25 and FoxP3 expression. Statistical significance
was considered to be achieved when p was less than 0.05. Data are
presented as mean 6 SD.
Results
Identification and Isolation of CD25+ CMV-T from G-CSF-
mobilized and Non-mobilized PBMCs
The kinetics of activation induced CD25 expression on
CMVpp65 peptide stimulated PBMCs was assessed in G-CSF-
mobilized donors to determine the optimal time for maximal
expression and compared directly against conventional non-
mobilized PBMCs. Baseline CD25 expression was assessed prior
to CMVpp65 stimulation amongst CD3+ T cells with no
significant difference observed between G-CSF-mobilized (4.5%
60.59) and non-mobilized (4.3% 60.59; p=0.83) PBMCs.
PBMCs were stimulated over 24 hours, sampled at 1, 4, 6, 16
and 24 hours and analysed for CD25 expression by flow cytometry
(Fig. 1A). The mean antigen-dependent expression of CD25 was
maximal at 24 hours in G-CSF-mobilized PBMCs (7.63% 61.12)
and was significantly elevated when compared to non-mobilized
PBMCs (4.33% 60.84; p=0.04). Further analysis of CD25
expression in G-CSF-mobilized PBMCs revealed the optimal
time of expression to be at 16 hours after subtraction of the
unstimulated control when compared with 24 hour stimulation
(3.20% 61.43 vs. 2.25% 60.76). On the basis of the results from
expression kinetics, isolation of CD25+ CMV-T was investigated
following 16 hour CMVpp65 peptide stimulation. A single
enrichment step was performed using magnetic-bead based cell
separation in six G-CSF-mobilized and five non-mobilized healthy
CMV-seropositive donors. No significant difference was observed
in CD25+ purity (86.9% 63.1 vs. 82.3% 69.9; p=0.32) or yield
(26.1% 68.8 vs. 11.3% 66.9; p=0.12) when comparing G-CSF-
mobilized and non-mobilized PBMCs (Fig. 1B). Yield was defined
as the absolute number of CD25+ T cells in the positive fraction as
a proportion of the absolute number of CD25+ T cells in the pre-
sort sample. Analysis of CD3+ T cell subsets in CD25 positive
fractions revealed a predominantly CD4+ population in both G-
CSF-mobilized (97.6% 61.8) and non-mobilized (92.3% 64.9)
PBMCs.
Figure 7. Assessment of FoxP3 expression and suppressive capacity of CD25+ expanded cells in G-CSF-mobilized PBMCs. FoxP3
expression was assessed in G-CSF-mobilized CD25+ expanded cells after 14–24 days in culture. FACS plots illustrate results in 3 expansion
experiments (A). FoxP3 expression was compared between CD25+ expanded cells (n=5) and CD25+ fractions following magnetic enrichment (n= 5)
(B). Suppression of CFSE-labelled PBMCs proliferation by CD25+ expanded cells (n= 3) was determined at three ratios in the presence of anti-CD3
antibody cultured for 5 days (C). PBMCs alone (CFSE) and PBMCs incubated with anti-CD3 antibody were cultured as experimental controls.
Assessment of suppressive capacity was determined by comparing CD25+ expanded cells with CD25+ fractions (D). ***p,0.0001, in an unpaired t
test.
doi:10.1371/journal.pone.0085911.g007
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FoxP3 Expression in CD25+ CMV-T
To evaluate the suitability of CD25 as a target for isolation of
CMV-T from G-CSF-mobilized PBMCs, the level of Treg
enrichment was determined by analysing the proportion of
CD25+FoxP3+ cells amongst CD4+ cells at three time points:
(1) pre-CMVpp65 stimulation; (2) post-CMVpp65 stimulation;
and (3) post-CD25 enrichment. Figure 1C illustrates a represen-
tative experiment in both a G-CSF-mobilized and non-mobilized
donor showing the increased level of CD25+FoxP3+ expression
present in G-CSF-mobilized PBMCs post CD25 enrichment.
Figure 1D summarizes experiments from six G-CSF-mobilized
and five non-mobilized donors where analysis revealed that the
proportion of FoxP3+ cells contained within the CD4+CD25+
population was significantly increased in G-CSF-mobilized
PBMCs in resting PBMCs (41.35% 68.41 vs. 17.5% 66.5;
p=0.04) and following CMVpp65 stimulation (42.79% 64.07 vs.
20.84% 65.46; p=0.012), when compared with non-mobilized
PBMCs. The proportion of CD25+FoxP3+ cells after CD25
enrichment was also shown to be significantly increased in G-CSF-
mobilized (73.64% 64.88) vs. non-mobilized (43.82% 65.64;
p=0.004) PBMCs.
Assessment of Suppressive Capacity of CD25+ enriched
CMV-T in G-CSF-mobilized PBMCs
Having demonstrated that CD25+ cells enriched after
CMVpp65 stimulation from G-CSF-mobilized PBMCs contain a
significant proportion of FoxP3-expressing cells, their suppressive
activity was assessed using a CFSE-based T cell proliferation assay.
The suppressive capacity of CD25+ T cells enriched after
CMVpp65 stimulation was compared to the CD252 fraction, in
both G-CSF-mobilized (n=5) and non-mobilized PBMCs (n=5).
Both fractions were cultured at ratios of 1:1 and 2:1 and in some
experiments at 5:1 (effectors: responders), with CFSE-labelled
PBMCs, in the presence of the superantigen SEB. Figure 2A
illustrates a representative experiment from a G-CSF-mobilized
donor, where T cell proliferation in the presence of CD252 cells
was similar to PBMCs alone (10.4% undivided CD3+ T cells) at
both 1:1 (12.5% undivided CD3+ T cells) and 2:1 (10.0%
undivided CD3+ T cells). In contrast, T cell proliferation was
greatly reduced when CFSE-labelled PBMCs were cultured in the
presence of CD25+ CMV-T at both 1:1 (57.3% undivided CD3+
T cells) and 2:1 (61.7% undivided CD3+ T cells), highlighting a
strong suppressive capacity. Suppression of T cell proliferation by
CD25+ CMV-T isolated from non-mobilized PBMCs was shown
to be reduced when compared with G-CSF-mobilized PBMCs.
Figure 2B shows the results from a representative experiment using
non-mobilized PBMCs, where proliferation of CFSE-labelled
PBMCs in response to SEB stimulation was comparable when
cultured with CD252 and CD25+ cells at both ratios of 1:1
(15.3% vs. 19.9% undivided CD3+ T cells) and 2:1 (14.1% vs.
27.7% respectively). Cumulative analysis of CD25+ enriched T
cells following CMVpp65 stimulation revealed a significant
difference in the mean suppressive capacity of G-CSF-mobilized
(n=5) compared to non-mobilized (n=5) PBMCs (Fig 2C). G-
CSF-mobilized PBMCs were highly suppressive of autologous
PBMCs proliferation following SEB stimulation at both ratios of
1:1 (62.7% 611.75 suppression) and 2:1 (63.58% 610.27). This
was significantly reduced in non-mobilized PBMCs at both ratios
of 1:1 (7.90% 64.79; p=0.007) and 2:1 (6.37% 63.48; p=0.002)
PBMCs.
Depletion of CD25-expressing Cells in Resting G-CSF-
mobilized PBMCs
To determine the role of Tregs in CD25+ T cell responses to
CMVpp65 peptide stimulation following isolation from G-CSF-
mobilized PBMCs, we depleted CD25 expressing cells prior to
stimulation. CD25-depleted G-CSF-mobilized PBMCs were
compared to unmanipulated PBMCs to assess the impact on
CD25 purity, yield and FoxP3 expression following CMVpp65
stimulation and CD25 magnetic enrichment. Mean CD25
expression amongst CD3+ T cells in CD25 depleted G-CSF-
mobilized PBMCs, pre stimulation, was 0.57% 60.13 compared
to 2.85% 60.69 (p=0.05) in the unmanipulated paired samples.
CD25 expression post CMVpp65 stimulation amongst CD4+ T
cells (Fig. 3A) was reduced when comparing unmanipulated
(4.40% 60.61) and CD25-depleted G-CSF-mobilized PBMCs
(1.75% 60.59). CD25+ FoxP3 expression was assessed pre and
post CD25 enrichment to determine the impact of CD252deple-
tion on the significant proportion of Tregs identified in CD25+
fractions following immunomagnetic CD25-enrichment. CD25-
depletion significantly reduced FoxP3 expression (Figs. 3B–C) both
pre CD25 enrichment (3.88% 60.51 vs. 0.74% 60.55; p=0.002)
and post CD25 enrichment (68.60% 65.56 vs. 11.59% 65.75;
p=0.001) in G-CSF-mobilized PBMCs. Assessment of CD25
expression following CMVpp65 stimulation and CD25 enrich-
ment revealed that CD25-depeletion had a significantly negative
impact on CD25 purity when comparing depleted versus
unmanipulated (17.08% 612.78 vs. 88.91% 60.57 respectively;
p=0.03) in G-CSF-mobilized PBMCs (Figure 3D). However,
analysis of mean CD25+FoxP32 T cells amongst CD4+ T cells
following enrichment revealed no significance (p.0.05) between
CD25-depleted (16.93% 66.34) and unmanipulated (22.20%
67.18) G-CSF-mobilized PBMCs, suggesting that CD25 deple-
tion does not remove CMVpp65-specific T cells.
Expansion of in-vitro Expanded CD25+ CMV-T and
Assessment of CMV Specificity
CD25+ CMV-T were cultured for up to 24 days in complete
medium supplemented with IL-7 and IL-15 in the presence of
autologous irradiated feeder cells. The mean proliferative capacity
of G-CSF-mobilized CD25+ (90.3-fold expansion 630.0; n=5)
was reduced (p=0.07) when compared with non-mobilized
CD25+ CMV-T (237.0-fold expansion 663.8; n=5) Expanded
cells from G-CSF-mobilized PBMCs revealed a higher proportion
of CD4+ T cells compared with non-mobilized PBMCs (44.13%
617.0 vs. 13.9%65.9) and a reduction in the proportion of CD8+
T cells (53.0% 617.3 vs. 79.1% 68.7). In two of the five CD25
expansion experiments performed from G-CSF-mobilized donors,
the CD8+ subset at day 22 accounted for .90% of CD3+ T cells
compared with ,5.5% CD4+, which was contradictory to the
results seen in the remaining three CD25 expansions and
illustrates a high level of donor variability in cultured cells, not
seen in the non-mobilized setting (Fig. 4A). Cultures showed
specificity for CMVpp65, determined by up-regulation of CD25+
and CD69+ expression following re-challenge with autologous
CMVpp65-loaded PBMCs in contrast to re-challenge with
autologous PBMCs without peptide (Fig. 4B). The mean level of
CD25+ CD69+ co-expression in CD25+ expanded CMV-T from
G-CSF-mobilized (64.9% 615.7) PBMCs was elevated when
compared to non-mobilized (35.4% 66.2) PBMCs. In control
experiments, re-challenge with autologous PBMCs alone produced
a low mean level of CD25+ CD69+ co-expression in CD25+
expanded CMV-T from G-CSF-mobilized (10.0%64.9) and non-
mobilized (5.0% 61.7) PBMCs.
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CD25+ Expanded Cells Synthesize and Secrete an
Effector Cytokine Repertoire and Effectively Lyse
CMVpp65 Targets
Antigen specificity was assessed through intracellular cytokine
staining (ICS) following CMVpp65 re-challenge (G-CSF-mobi-
lized, n=5; non-mobilized, n=5). CD25+ expanded cells revealed
low to undetectable mean levels of IL-10 secretion after
CMVpp65 re-challenge from both G-CSF-mobilized (0.11%
60.05) and non-mobilized (0.41% 60.10) PBMCs. Expanded
cells synthesized and secreted low levels of IL-2 and significant
levels of TNF-a, IFN-c and Granzyme B (Figs. 5A–B), indicating
that cells possessed the effector molecules necessary for cytotoxic
activity. Cytokine secretion was comparable between G-CSF-
mobilized and non-mobilized CD25+ expanded cells, apart from
IFN-c where G-CSF-mobilized CD25+ CMV-T revealed a
significant increase (p=0.009) in secretion compared with non-
mobilized CD25+ CMV-T (78.4% 65.2 vs. 46.7% 67.7). In
experiments where CD25+ expanded cells were re-challenged
with unstimulated or CMV IE-1 peptide loaded autologous
PBMCs minimal cytokine secretion was observed (data not
shown).
Cytotoxic activity was evaluated using autologous PHA blasts
loaded with CMVpp65 peptides and labelled with Calcein-AM
dye as targets. CD25+ expanded cells from both G-CSF-mobilized
(n=4) and non-mobilized (n=4) PBMCs effectively lysed
CMVpp65 targets at all E: T ratios in a dose-dependent manner
(Figs. 6A–B), with minimal lysis of PHA blasts without CMVpp65
peptides. Comparison between G-CSF-mobilized and non-mobi-
lized CD25+ CMV-T revealed no significant difference in lysis of
CMVpp65 PHA blasts at any of the E:T ratios.
Assessment of FoxP3 Expression and Suppressive
Capacity of CD25+ Expanded CMV-T from G-CSF-
mobilized PBMCs
Previous experiments identified that CD25+ cells enriched from
G-CSF-mobilized PBMCs following CMVpp65 peptide stimula-
tion contained a significant proportion of FoxP3 expressing cells.
Assessment of FoxP3 expression in CD25 expanded cells after
short term culture is illustrated in three expansions (Fig. 7A) and
revealed a significant reduction (p=,0.0001) in expression
compared to pre-expansion. Mean FoxP3 expression amongst
CD4+ T cells after culture was 9.89% 64.02, compared to
64.24% 64.88 at pre-expansion (Fig. 7B). The suppressive
capacity of CD25+ expanded cells from G-CSF-mobilized PBMCs
were assessed in a 5-day CFSE proliferation assay (Fig. 7C) as
previously described. G-CSF-mobilized CD25+ expanded cells
were shown to retain their suppressive capacity at all ratios at a
level comparable with CD25 enriched cells post CMVpp65
stimulation (Fig. 7D). Mean suppression of autologous PBMCs
when co-cultured at 1:2 with CD25+ expanded cells was 51.35%
61.05 compared with 63.58%610.27 with CD25+ enriched cells.
Discussion
CD25 expression has been reported as an optimal marker for
the identification of antigen-specific T cells following peptide
stimulation [17–21], enabling the magnetic enrichment of
activated anti-viral T cells that would otherwise be undetectable
using current IFN-c secretion methods. Generation of anti-viral T
cells has been largely restricted to non-mobilized steady state
leukapheresis or a single blood draw for manufacture. More
recently, studies have investigated the use of G-CSF-mobilized
PBMCs from the original aHSCT graft as a potential source for
CMV-T manufacture [31;32]. Here, we expand on these studies
to investigate the activation marker CD25 as a possible target and
investigate the nature of CD25+ enriched cells following CMV
peptide stimulation with regard to Treg characterisation, due to
their increased number following G-CSF-mobilization [36].
We have shown that CD25 expression is up-regulated in G-
CSF-mobilized PBMCs after CMVpp65 peptide stimulation at a
level comparable to that seen in non-mobilized PBMCs and that
magnetic enrichment of CD25 expressing cells results in a high
level of purity. However further analysis revealed that the CD25
positive fractions isolated from G-CSF-mobilized PBMCs co-
expressed FoxP3, a population that was largely absent in the
CD25 positive fraction isolated from non-mobilized PBMCs.
Functional studies revealed they were highly suppressive in vitro,
demonstrating a significant population of Tregs. Several studies
have indicated the existence of anti-viral Tregs, revealed following
antigenic stimulation [37–42] and indeed Ltjens and colleagues
concluded that CD4+CD25+CD1272FoxP3+ Tregs contained a
population of CMV-specific T cells [38], which is consistent with
the results seen here. This suggests that CMVpp65 stimulation in
G-CSF-mobilized PBMCs induces a population of antigen-specific
CD25+ Tregs that are able to recognize CMVpp65 peptides and
possibly proliferate in response to engagement of their cognate
antigen. Support for this hypothesis is evident in a murine model
of Leishmania infection, in which Tregs proliferated in response to
recognition of parasite derived antigen [40]. Previous studies [21]
have suggested that the co-infusion of Tregs and anti-viral T cells
could be advantageous in terms of an immunotherapy that inhibits
GvHD on one hand and promotes ant-viral immune reconstitu-
tion on the other. It has also been argued that it is unlikely that
infused Tregs will prevent proliferation of virus-specific T cells; a
hypothesis supported by studies in mice demonstrating co-infusion
of Tregs and conventional T cells (Tcons) enhances virus-specific
immune reconstitution and protected mice from lethal CMV
infection in the HSCT setting [43]. Clinical studies have since
demonstrated that early infusion of freshly isolated donor Tregs
followed by Tcons at the time of full-haplotype-mismatched
aHSCT prevented GvHD in the absence of any post-transplant
immunosuppression and improved immunity to opportunistic
pathogens [44]. However in this study Tregs were generated from
steady-state leukapheresis and did not use viral antigen-specific
Tregs which appear to be preferentially generated from G-CSF-
mobilized PBMCs.
In the context of manufacturing CMV-T for adoptive
immunotherapy the emergence of a population of CD25+FoxP3+
cells from G-CSF-mobilized PBMCs with a highly suppressive
capacity suggests that CD25 will be an unsuitable target for CMV-
T isolation. We therefore investigated the impact of depleting
CD25-expressing cells prior to CMVpp65 peptide stimulation in
order to eliminate the CD25+FoxP3+ cells identified following
enrichment from G-CSF-mobilized PBMCs. Depletion of CD25
expressing cells in G-CSF-mobilized PBMCs, prior to CMVpp65
peptide stimulation, resulted in a reduction in CD25 expression
post stimulation which in turn had a negative impact on both yield
and purity following CD25 enrichment, confirming previous
studies by Melenhorst and colleagues in non-mobilized PBMCs
(39). The reduction in CD25 expression is partly explained by the
elimination of contaminating Tregs prior to CMVpp65 stimula-
tion, as indeed was the aim, but could also be attributed to a
population of CMV-T that are in an activated state and express
CD25 prior to CMVpp65 stimulation in vitro. Although a
significant reduction in FoxP3 expression was observed in
CD25-depleted PBMCs post-CMVpp65 stimulation, FoxP3
expression post-CD25 enrichment was still detectable. These
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results suggest either the emergence of newly expressing FoxP3
cells or persistence of FoxP3+CD25– cells following the depletion
step and comparable to results seen in non-mobilized cells [39–42]
and supports the concept of CMV-specific Tregs.
To determine the functionality of CD25+ CMV-T and the
possible impact of Tregs on the anti-CMV response, we analysed
whether these cells were capable of secreting inflammatory
cytokines in response to antigenic re-challenge following short-
term culture. CD25+ expanded cells from G-CSF-mobilized
PBMCs secreted high levels of IFN-c and Granzyme B, and to a
lesser extent TNF-a and IL-2, in the absence of IL-10. This
cytokine profile is in keeping with anti-viral CTL rather than
antigen-specific Tregs, which was confirmed by their ability to lyse
autologous CMV-pulsed target cells. Further analysis of FoxP3
expression also revealed a significant reduction following expan-
sion. Nonetheless expanded CD25+ CMV-T retained a capacity
to suppress polyclonal T cells proliferation suggesting the presence
of a population of FoxP3– IL10– Tregs. However it must be noted
that a limitation of this study was the failure to procure paired
donor samples before and after G-CSF-mobilization for subse-
quent comparison of both the CMV immune response and Treg
numbers and potency. The use of paired samples could have
allowed for stronger statistical analysis to be made when analysing
the effect of G-CSF-mobilization given the knowledge of high
donor variability that exists, in terms of the CMV immune
response.
Although FoxP3 generally identifies natural thymus-derived
Tregs, adaptive Tregs may or may not express this transcription
factor [45]. Studies have also indicated that FoxP3 expression can
be induced in human CD4+ effector T cells after activation as a
normal consequence of CD4+ T cell activation [42–46] and that
IFN-c and IL-2 production are not suppressed in FoxP3+ effector
T cells [47,48], thus bringing into doubt its validity as an exclusive
marker of Tregs. The characterisation of the pool of
CD25+FoxP3+ Tregs identified post CD25 enrichment following
CMVpp65 stimulation and the subsequent loss of FoxP3
expression following short-term culture highlights the need for
future studies. Most notably to extensively characterise these
highly suppressive cells with regard to disseminating between
inducible/adaptive and antigen-specific subsets of Tregs, that may
be committed to regulating specific arms of the immune response.
In conclusion our data indicates that CD25 enrichment post
CMV stimulation in G-CSF-mobilized PBMCs results in the
simultaneous generation of a functional mixed population of
CMV-T and Tregs and outlines a potential therapeutic strategy
for the treatment of both GvHD and CMV reactivation following
HSCT. The use of G-CSF-mobilized PBMCs represents a feasible
approach to alleviating the many problems incurred with
successive donations and procurement of cells from unrelated
donors and thereby simplifying the clinical application of cellular
therapy manufacture in the aHSCT setting. Questions remain as
to whether these cells are capable of both conferring protection
from CMV and minimising the GvH response in vivo and whether
the infused Treg population will prevent the persistence and
proliferation of CMV-T, both of which can only be answered by
clinical trials utilizing this approach, in recipients of aHSCT.
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